Evangelos Papachristou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Evangelos Papachristou has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Marios Papasotiriou
Department of Nephrology and Kidney Transplantation, University Hospital of Patras, 26504 Patras, Greece
11 shared publications - Dimitrios S. Goumenos
Department of Nephrology, University Hospital of Patras, 26504 Patras, Greece
8 shared publications Dimitrios Goumenos
Department of Nephrology and Renal Transplantation, Patras University Hospital , Patras 26504
3 shared publications- Marieta P. Theodorakopoulou
First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki , Thessaloniki
3 shared publications - Vassilios Liakopoulos
Department of Nephrology, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
3 shared publications Adamantia Bratsiakou
Department of Nephrology and Kidney Transplantation, University Hospital of Patras , Patras , Greece
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2587
Treatment Patterns of Patients with Hyperkalaemia Receiving Sodium Zirconium Cyclosilicate in Greece: A Multicenter Prospective Study
Background/Objectives: Hyperkalaemia affects 2–4% of the general population. Real-world data in Greece are currently limited. The SHIELD study assessed treatment patterns and disease management of patients with hyperkalaemia in Greece. Methods: This prospective, multicenter, observational study was conducted in 12 hospital-based nephrology and cardiology units across Greece, with 11 having enrolled patients. The study enrolled patients with hyperkalaemia and chronic kidney disease (CKD) on dialysis or not, or heart failure (HF) under RAASi/MRAs, receiving sodium zirconium cyclosilicate (SZC), with a 6-month follow-up. Results: Overall, 125 patients participated in the study (51.2% CKD non-dialysis, 25.6% CKD on dialysis, and 23.2% HF patients receiving RAASi/MRAs), with a mean age of 64.7 years. At SZC initiation, the overall median serum potassium was 5.6 mmol/L (range: 5.1–7.7). At Visits 1, 2, and 3, the most frequently reported potassium monitoring interval was monthly (44.8%, 40.0%, and 41.4%, respectively). The overall median eGFR as calculated by CKD-EPI 2021 equation changed from 30.0 mL/min/1.73 m2 at baseline to 24.5 at 3 months, and 27.0 at 6 months. CKD non-dialysis patients mostly received 10 g SZC daily, dialysis patients 5 g on non-dialysis days and HF patients 5 g daily, with limited changes over time. SZC plus an RAASi/MRA, mostly ARBs (72.2%), was administered to 63.2% of patients at baseline and 3 months, increasing to 69.0% at 6 months. A total of 84.8% of patients received antihypertensive, 56.8% lipid-lowering, 39.2% antiplatelet, 40.0% antidiabetic and 4.8% corticosteroid agents. Conclusions: The SHIELD study provides real-world evidence on patient characteristics, monitoring practices, and treatment patterns, including the combination of SZC and RAASi/MRAs, in patients with hyperkalaemia in Greece.
- 10 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2587
Open AccessTreatment Patterns of Patients with Hyperkalaemia Receiving Sodium Zirconium Cyclosilicate in Greece: A Multicenter Prospective Study
Background/Objectives: Hyperkalaemia affects 2–4% of the general population. Real-world data in Greece are currently limited. The SHIELD study assessed treatment patterns and disease management of patients with hyperkalaemia in Greece. Methods: This prospective, multicenter, observational study was conducted in 12 hospital-based nephrology and cardiology units across Greece, with 11 having enrolled patients. The study enrolled patients with hyperkalaemia and chronic kidney disease (CKD) on dialysis or not, or heart failure (HF) under RAASi/MRAs, receiving sodium zirconium cyclosilicate (SZC), with a 6-month follow-up. Results: Overall, 125 patients participated in the study (51.2% CKD non-dialysis, 25.6% CKD on dialysis, and 23.2% HF patients receiving RAASi/MRAs), with a mean age of 64.7 years. At SZC initiation, the overall median serum potassium was 5.6 mmol/L (range: 5.1–7.7). At Visits 1, 2, and 3, the most frequently reported potassium monitoring interval was monthly (44.8%, 40.0%, and 41.4%, respectively). The overall median eGFR as calculated by CKD-EPI 2021 equation changed from 30.0 mL/min/1.73 m2 at baseline to 24.5 at 3 months, and 27.0 at 6 months. CKD non-dialysis patients mostly received 10 g SZC daily, dialysis patients 5 g on non-dialysis days and HF patients 5 g daily, with limited changes over time. SZC plus an RAASi/MRA, mostly ARBs (72.2%), was administered to 63.2% of patients at baseline and 3 months, increasing to 69.0% at 6 months. A total of 84.8% of patients received antihypertensive, 56.8% lipid-lowering, 39.2% antiplatelet, 40.0% antidiabetic and 4.8% corticosteroid agents. Conclusions: The SHIELD study provides real-world evidence on patient characteristics, monitoring practices, and treatment patterns, including the combination of SZC and RAASi/MRAs, in patients with hyperkalaemia in Greece.
- Open Access
- 9 July 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
Prophylactic interventions for focal segmental glomerulosclerosis recurrence after kidney transplantation: a systematic review and network meta-analysis
Themistoklis Paraskevas, Anna Kanta, Panagiota Perdiki, Evangelos Papachristou, Marios Papasotiriou. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0102
- 9 July 2026
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
Open AccessProphylactic interventions for focal segmental glomerulosclerosis recurrence after kidney transplantation: a systematic review and network meta-analysis
Themistoklis Paraskevas, Anna Kanta, Panagiota Perdiki, Evangelos Papachristou, Marios Papasotiriou. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0102
- Open Access
- 29 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
May Measurement Month 2023: Implementation of a global opportunistic blood pressure screening campaign in Greece
The May Measurement Month (MMM) 2023 global blood pressure (BP) screening campaign was conducted in Greece aiming to raise hypertension awareness and control in the general population. Volunteers aged ≥18 years were recruited through opportunistic screening in 11 cities. Each participant was assessed with triplicate seated BP measurements using validated automated upper-arm cuff devices and a standardized questionnaire on medical history. These data were submitted online through a custom-designed app of the global MMM campaign. Hypertension was defined as BP ≥140/90mmHg (average of second-third measurement) and/or use of antihypertensive drugs. A total of 5,437 individuals were analysed (mean age 53±17.1 years, 46.2% men, 27.8% current smokers, 10.9% with diabetes, 6.7% with cardiovascular disease) and 41.7% were hypertensive. The prevalence of hypertension was higher in men compared to women and in older compared to youngers individuals. Among hypertensives, 73.9% were unaware of their diagnosis, 69.9% were on antihypertensive drugs, and 47.6% were treated and controlled (BP <140/90mmHg). These data suggest that in Greece a high prevalence of hypertension persists, and often is undiagnosed, untreated, and uncontrolled. Global BP screening campaigns such as MMM are important and need to be complemented by public health initiatives at a national level for improving hypertension diagnosis and control.
- 29 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
Open AccessMay Measurement Month 2023: Implementation of a global opportunistic blood pressure screening campaign in Greece
The May Measurement Month (MMM) 2023 global blood pressure (BP) screening campaign was conducted in Greece aiming to raise hypertension awareness and control in the general population. Volunteers aged ≥18 years were recruited through opportunistic screening in 11 cities. Each participant was assessed with triplicate seated BP measurements using validated automated upper-arm cuff devices and a standardized questionnaire on medical history. These data were submitted online through a custom-designed app of the global MMM campaign. Hypertension was defined as BP ≥140/90mmHg (average of second-third measurement) and/or use of antihypertensive drugs. A total of 5,437 individuals were analysed (mean age 53±17.1 years, 46.2% men, 27.8% current smokers, 10.9% with diabetes, 6.7% with cardiovascular disease) and 41.7% were hypertensive. The prevalence of hypertension was higher in men compared to women and in older compared to youngers individuals. Among hypertensives, 73.9% were unaware of their diagnosis, 69.9% were on antihypertensive drugs, and 47.6% were treated and controlled (BP <140/90mmHg). These data suggest that in Greece a high prevalence of hypertension persists, and often is undiagnosed, untreated, and uncontrolled. Global BP screening campaigns such as MMM are important and need to be complemented by public health initiatives at a national level for improving hypertension diagnosis and control.
- Open Access
- 6 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (5) , 482
Impact of a Single Hemodialysis Session on Oxidative Stress-Inducing and Oxidative Damage Biomarkers in End-Stage Kidney Disease Patients
Oxidative stress (OS) is elevated in patients with end-stage kidney disease undergoing maintenance dialysis and contributes to increased cardiovascular risk. While kidney dysfunction and dialysis can generate OS, the acute effects of a single dialysis session remain unclear due to variability in study design and the biomarkers used. In this observational study, blood samples from 68 hemodialysis patients were collected before and after a single session. Plasma levels of the reactive oxygen species marker superoxide (O2•−) and OS-damage marker lipid hydroperoxides (LOOHs), protein-bound malondialdehyde (PrMDA), protein-bound thiobarbituric acid reactive substances (PrTBARSs), and protein carbonyls (PrCOs) were measured. LOOHs increased significantly by 50% post-dialysis, whereas PrMDA and PrTBARSs decreased modestly by ~10%. No significant changes were observed in O2•− or PrCOs. Dialysis vintage correlated positively with LOOHs, PrMDA, and PrTBARSs, but not with O2•− or PrCOs. No significant associations were found between OS markers and comorbidities, medication or sex. The post-dialysis rise in LOOHs, an early-formed and least accumulating lipid peroxidation marker, may reflect acute changes in OS during a single HD session. The rising association of PrMDA and PrTBARSs with dialysis vintage may suggest cumulative OS over time.
- 6 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (5) , 482
Open AccessImpact of a Single Hemodialysis Session on Oxidative Stress-Inducing and Oxidative Damage Biomarkers in End-Stage Kidney Disease Patients
Oxidative stress (OS) is elevated in patients with end-stage kidney disease undergoing maintenance dialysis and contributes to increased cardiovascular risk. While kidney dysfunction and dialysis can generate OS, the acute effects of a single dialysis session remain unclear due to variability in study design and the biomarkers used. In this observational study, blood samples from 68 hemodialysis patients were collected before and after a single session. Plasma levels of the reactive oxygen species marker superoxide (O2•−) and OS-damage marker lipid hydroperoxides (LOOHs), protein-bound malondialdehyde (PrMDA), protein-bound thiobarbituric acid reactive substances (PrTBARSs), and protein carbonyls (PrCOs) were measured. LOOHs increased significantly by 50% post-dialysis, whereas PrMDA and PrTBARSs decreased modestly by ~10%. No significant changes were observed in O2•− or PrCOs. Dialysis vintage correlated positively with LOOHs, PrMDA, and PrTBARSs, but not with O2•− or PrCOs. No significant associations were found between OS markers and comorbidities, medication or sex. The post-dialysis rise in LOOHs, an early-formed and least accumulating lipid peroxidation marker, may reflect acute changes in OS during a single HD session. The rising association of PrMDA and PrTBARSs with dialysis vintage may suggest cumulative OS over time.
- Open Access
- 2 April 2026
- Published by MDPI AG in Preprints.org
Impact of a Single Hemodialysis Session on Oxidative Stress-Inducing and Oxidative Damage Biomarkers in End-Stage Kidney Disease Patients
Oxidative stress (OS) is elevated in patients with end-stage kidney disease undergoing maintenance dialysis and contributes to increased cardiovascular risk. While kidney dysfunction and dialysis can generate OS, the acute effects of a single dialysis session remain unclear due to variability in study design and biomarkers used. In this observational study, blood samples from 68 hemodialysis patients were collected before and after a single session. Plasma levels of the reactive oxygen species marker superoxide (O2•−) and OS-damage markers lipid hydroperoxides (LOOH), protein-bound malondialdehyde (PrMDA), protein-bound thiobarbituric acid reactive substances (PrTBARS), and protein carbonyls (PrCO) were measured. LOOH increased significantly by 50% post-dialysis, whereas PrMDA and PrTBARS decreased modestly by ~10%. No significant changes were observed in O2•− or PrCO. Dialysis vintage correlated positively with LOOH, PrMDA, and PrTBARS, but not with O2•− or PrCO. Patients undergoing low-flux hemodialysis exhibited a greater post-dialysis increase in LOOH than those treated with high-flux hemodialysis. No significant associations were found between OS markers and comorbidities or medication. The post-dialysis rise in LOOH, an early-formed and least accumulating lipid peroxidation marker, highlights its sensitivity to acute dialysis-related oxidative changes. The rising tendency of PrMDA and PrTBARS with dialysis vintage suggests cumulative OS over time.
- 2 April 2026
- Published by MDPI AG in Preprints.org
Open AccessImpact of a Single Hemodialysis Session on Oxidative Stress-Inducing and Oxidative Damage Biomarkers in End-Stage Kidney Disease Patients
Oxidative stress (OS) is elevated in patients with end-stage kidney disease undergoing maintenance dialysis and contributes to increased cardiovascular risk. While kidney dysfunction and dialysis can generate OS, the acute effects of a single dialysis session remain unclear due to variability in study design and biomarkers used. In this observational study, blood samples from 68 hemodialysis patients were collected before and after a single session. Plasma levels of the reactive oxygen species marker superoxide (O2•−) and OS-damage markers lipid hydroperoxides (LOOH), protein-bound malondialdehyde (PrMDA), protein-bound thiobarbituric acid reactive substances (PrTBARS), and protein carbonyls (PrCO) were measured. LOOH increased significantly by 50% post-dialysis, whereas PrMDA and PrTBARS decreased modestly by ~10%. No significant changes were observed in O2•− or PrCO. Dialysis vintage correlated positively with LOOH, PrMDA, and PrTBARS, but not with O2•− or PrCO. Patients undergoing low-flux hemodialysis exhibited a greater post-dialysis increase in LOOH than those treated with high-flux hemodialysis. No significant associations were found between OS markers and comorbidities or medication. The post-dialysis rise in LOOH, an early-formed and least accumulating lipid peroxidation marker, highlights its sensitivity to acute dialysis-related oxidative changes. The rising tendency of PrMDA and PrTBARS with dialysis vintage suggests cumulative OS over time.
- Open Access
- 16 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5747
Efficacy of Expanded Hemodialysis and Comparison with Standard Hemodialysis and Online Hemodiafiltration
Patients on standard hemodialysis (HD) show insufficient clearance of medium-molecular-weight uremic toxins, resulting in long-term complications. In this study we investigated the effectiveness of expanded HD (xHD) in the clearance of medium-molecular-weight uremic substances. This prospective study included patients on standard thrice-weekly HD. Participants were treated with xHD for 4 weeks, and the clearance of urea and β2-microglobulin was measured at the beginning and at the end of the study and compared with standard HD (sHD). Moreover, we investigated the clearance of Su-PAR, MCP-1, and activin, comparing sHD, xHD, and online hemodiafiltration (HDF). xHD had the same efficiency in the removal of low-molecular-weight substances compared to sHD but led to a significant decrease in β2-microglobulin levels from the first application of the method (sHD: from 36.9 ± 10.6 to 39.7 ± 18.9 mg/dL, p = 0.595 vs. 1st xHD: from 40 (36.5, 41.8) to 11 (9.8, 13.2) mg/dL, p = 0.008 vs. after 4 weeks on xHD: from 31.5 (28.5, 34.5) to 8.7 (8.2, 9.0) mg/dL, p = 0.008). Moreover, pre-session β2-microglobulin levels significantly decreased after 4 weeks on xHD. Su-PAR, MCP-1, and activin during xHD were also significantly reduced. xHD leads to a significant and cumulative reduction in medium-molecular-weight uremic toxins compared to standard HD.
- 16 June 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (12) , 5747
Open AccessEfficacy of Expanded Hemodialysis and Comparison with Standard Hemodialysis and Online Hemodiafiltration
Patients on standard hemodialysis (HD) show insufficient clearance of medium-molecular-weight uremic toxins, resulting in long-term complications. In this study we investigated the effectiveness of expanded HD (xHD) in the clearance of medium-molecular-weight uremic substances. This prospective study included patients on standard thrice-weekly HD. Participants were treated with xHD for 4 weeks, and the clearance of urea and β2-microglobulin was measured at the beginning and at the end of the study and compared with standard HD (sHD). Moreover, we investigated the clearance of Su-PAR, MCP-1, and activin, comparing sHD, xHD, and online hemodiafiltration (HDF). xHD had the same efficiency in the removal of low-molecular-weight substances compared to sHD but led to a significant decrease in β2-microglobulin levels from the first application of the method (sHD: from 36.9 ± 10.6 to 39.7 ± 18.9 mg/dL, p = 0.595 vs. 1st xHD: from 40 (36.5, 41.8) to 11 (9.8, 13.2) mg/dL, p = 0.008 vs. after 4 weeks on xHD: from 31.5 (28.5, 34.5) to 8.7 (8.2, 9.0) mg/dL, p = 0.008). Moreover, pre-session β2-microglobulin levels significantly decreased after 4 weeks on xHD. Su-PAR, MCP-1, and activin during xHD were also significantly reduced. xHD leads to a significant and cumulative reduction in medium-molecular-weight uremic toxins compared to standard HD.
- Open Access
- 10 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 10904
Circulating Immune Complexes and Complement Activation in Sensitized Kidney Transplant Recipients
Chronic antibody-mediated rejection in kidney transplantation is a common cause of graft loss in the late post-transplant period. In this process, the role of the classical complement activation pathway is crucial due to the formation of immune complexes between donor-specific antibodies (DSAs) and donor antigens and the attachment of the C1q complement fragment. This study aimed to determine the levels of circulating C1q immunocomplexes (CIC-C1q) and complement activation (CH50), in sensitized kidney transplant recipients (KTRs). In this cross-sectional study we used serum samples from KTRs with de novo or preformed DSAs (n = 14), KTRs without DSAs (n = 28), and 22 subjects with no history of chronic kidney disease (controls). C1q immunocomplexes and CH50 concentration in serum were measured with the enzyme immunoassay (EIA) kit MicroVue CIC-C1q (Quidel, Athens, OH, USA) and EIA kit MicroVue CH50 (Quidel, OH, USA), respectively. Higher concentrations of CIC-C1q was observed in KTRs with DSAs in comparison with controls and with KTRs with no DSAs (6.8 ± 2.7 and 4.8 ± 1.9 vs. 5.0 ± 1.2 μg Eq/mL, respectively, p < 0.01). We found no difference in CIC-C1q between KTRs with no DSAs and controls. CIC-C1q levels were positively correlated with DSA titer. CH50 levels were decreased in KTRs with DSAs in comparison with controls and KTRs with no DSAs (39 ± 15 vs. 68 ± 40 and 71 ± 34 U Eq/mL, respectively, p < 0.01). There was no difference in CH50 between DSA-negative KTRs and controls. Kidney transplant recipients with DSAs had increased serum levels of C1q immunocomplexes and increased classical pathway complement activation.
- 10 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (20) , 10904
Open AccessCirculating Immune Complexes and Complement Activation in Sensitized Kidney Transplant Recipients
Chronic antibody-mediated rejection in kidney transplantation is a common cause of graft loss in the late post-transplant period. In this process, the role of the classical complement activation pathway is crucial due to the formation of immune complexes between donor-specific antibodies (DSAs) and donor antigens and the attachment of the C1q complement fragment. This study aimed to determine the levels of circulating C1q immunocomplexes (CIC-C1q) and complement activation (CH50), in sensitized kidney transplant recipients (KTRs). In this cross-sectional study we used serum samples from KTRs with de novo or preformed DSAs (n = 14), KTRs without DSAs (n = 28), and 22 subjects with no history of chronic kidney disease (controls). C1q immunocomplexes and CH50 concentration in serum were measured with the enzyme immunoassay (EIA) kit MicroVue CIC-C1q (Quidel, Athens, OH, USA) and EIA kit MicroVue CH50 (Quidel, OH, USA), respectively. Higher concentrations of CIC-C1q was observed in KTRs with DSAs in comparison with controls and with KTRs with no DSAs (6.8 ± 2.7 and 4.8 ± 1.9 vs. 5.0 ± 1.2 μg Eq/mL, respectively, p < 0.01). We found no difference in CIC-C1q between KTRs with no DSAs and controls. CIC-C1q levels were positively correlated with DSA titer. CH50 levels were decreased in KTRs with DSAs in comparison with controls and KTRs with no DSAs (39 ± 15 vs. 68 ± 40 and 71 ± 34 U Eq/mL, respectively, p < 0.01). There was no difference in CH50 between DSA-negative KTRs and controls. Kidney transplant recipients with DSAs had increased serum levels of C1q immunocomplexes and increased classical pathway complement activation.
- Open Access
- 31 May 2024
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 86, 73-79
Prevalence, awareness, and control of hypertension in Greece before and after the COVID-19 pandemic: May Measurement Month survey 2019–2022
- 31 May 2024
- Published by Elsevier in Hellenic Journal of Cardiology
- Vol. 86, 73-79
Open AccessPrevalence, awareness, and control of hypertension in Greece before and after the COVID-19 pandemic: May Measurement Month survey 2019–2022
- Open Access
- 21 February 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (8) , sfae041
The effect of different dialysate sodium concentrations on ambulatory blood pressure in hemodialysis patients: a prospective interventional study
Hypertension is associated with increased morbidity and mortality in hemodialysis patients. Existing recommendations suggest reduction of sodium load, but the effect of dialysate sodium on blood pressure (BP) is not fully elucidated. The aim of the present study is to investigate the effect of different dialysate sodium concentrations on 72-h ambulatory BP in hemodialysis patients. This prospective study included patients on standard thrice-weekly hemodialysis. All patients initially underwent six sessions with dialysate sodium concentration of 137 meq/L, followed consecutively by another six sessions with dialysate sodium of 139 meq/L and, finally, six sessions with dialysate sodium of 141 meq/L. At the start of the sixth hemodialysis session on each sodium concentration, 72-h ABPM was performed over the long interdialytic interval to evaluate ambulatory systolic and diastolic BP (SBP and DBP) during the overall 72-h, different 24-h, daytime and night-time periods. Twenty-five patients were included in the final analysis. A significant increase in the mean 72-h SBP was observed with higher dialysate sodium concentrations (124.8 ± 16.6 mmHg with 137 meq/L vs 126.3 ± 17.5 mmHg with 139 meq/L vs 132.3 ± 19.31 mmHg with 141 meq/L, P = 0.002). Similar differences were noted for DBP; 72-h DBP was significantly higher with increasing dialysate sodium concentrations (75.1 ± 11.3 mmHg with 137 meq/L vs 76.3 ± 13.7 mmHg with 139 meq/L vs 79.5 ± 13.9 mmHg with 141 meq/L dialysate sodium, P = 0.01). Ambulatory BP during the different 24-h intervals, daytime and night-time periods was also progressively increasing with increasing dialysate sodium concentration. This pilot study showed a progressive increase in ambulatory BP with higher dialysate sodium concentrations. These findings support that lower dialysate sodium concentration may help towards better BP control in hemodialysis patients.
- 21 February 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (8) , sfae041
Open AccessThe effect of different dialysate sodium concentrations on ambulatory blood pressure in hemodialysis patients: a prospective interventional study
Hypertension is associated with increased morbidity and mortality in hemodialysis patients. Existing recommendations suggest reduction of sodium load, but the effect of dialysate sodium on blood pressure (BP) is not fully elucidated. The aim of the present study is to investigate the effect of different dialysate sodium concentrations on 72-h ambulatory BP in hemodialysis patients. This prospective study included patients on standard thrice-weekly hemodialysis. All patients initially underwent six sessions with dialysate sodium concentration of 137 meq/L, followed consecutively by another six sessions with dialysate sodium of 139 meq/L and, finally, six sessions with dialysate sodium of 141 meq/L. At the start of the sixth hemodialysis session on each sodium concentration, 72-h ABPM was performed over the long interdialytic interval to evaluate ambulatory systolic and diastolic BP (SBP and DBP) during the overall 72-h, different 24-h, daytime and night-time periods. Twenty-five patients were included in the final analysis. A significant increase in the mean 72-h SBP was observed with higher dialysate sodium concentrations (124.8 ± 16.6 mmHg with 137 meq/L vs 126.3 ± 17.5 mmHg with 139 meq/L vs 132.3 ± 19.31 mmHg with 141 meq/L, P = 0.002). Similar differences were noted for DBP; 72-h DBP was significantly higher with increasing dialysate sodium concentrations (75.1 ± 11.3 mmHg with 137 meq/L vs 76.3 ± 13.7 mmHg with 139 meq/L vs 79.5 ± 13.9 mmHg with 141 meq/L dialysate sodium, P = 0.01). Ambulatory BP during the different 24-h intervals, daytime and night-time periods was also progressively increasing with increasing dialysate sodium concentration. This pilot study showed a progressive increase in ambulatory BP with higher dialysate sodium concentrations. These findings support that lower dialysate sodium concentration may help towards better BP control in hemodialysis patients.
- Open Access
- 19 February 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (4) , 450
Monocyte Chemoattractant Protein-1 (MCP-1), Activin-A and Clusterin in Children and Adolescents with Obesity or Type-1 Diabetes Mellitus
Inflammation plays a crucial role in diabetes and obesity through macrophage activation. Macrophage chemoattractant protein-1 (MCP-1), activin-A, and clusterin are chemokines with known roles in diabetes and obesity. The aim of this study is to investigate their possible diagnostic and/or early prognostic values in children and adolescents with obesity and type-1 diabetes mellitus (T1DM). Methods: We obtained serum samples from children and adolescents with a history of T1DM or obesity, in order to measure and compare MCP-1, activin-A, and clusterin concentrations. Results: Forty-three subjects were included in each of the three groups (controls, T1DM, and obesity). MCP-1 values were positively correlated to BMI z-score. Activin-A was increased in children with obesity compared to the control group. A trend for higher values was detected in children with T1DM. MCP-1 and activin-A levels were positively correlated. Clusterin levels showed a trend towards lower values in children with T1DM or obesity compared to the control group and were negatively correlated to renal function. Conclusions: The inflammation markers MCP-1, activin-A, and clusterin are not altered in children with T1DM. Conversely, obesity in children is positively correlated to serum MCP-1 values and characterized by higher activin-A levels, which may reflect an already established systematic inflammation with obesity since childhood.
- 19 February 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (4) , 450
Open AccessMonocyte Chemoattractant Protein-1 (MCP-1), Activin-A and Clusterin in Children and Adolescents with Obesity or Type-1 Diabetes Mellitus
Inflammation plays a crucial role in diabetes and obesity through macrophage activation. Macrophage chemoattractant protein-1 (MCP-1), activin-A, and clusterin are chemokines with known roles in diabetes and obesity. The aim of this study is to investigate their possible diagnostic and/or early prognostic values in children and adolescents with obesity and type-1 diabetes mellitus (T1DM). Methods: We obtained serum samples from children and adolescents with a history of T1DM or obesity, in order to measure and compare MCP-1, activin-A, and clusterin concentrations. Results: Forty-three subjects were included in each of the three groups (controls, T1DM, and obesity). MCP-1 values were positively correlated to BMI z-score. Activin-A was increased in children with obesity compared to the control group. A trend for higher values was detected in children with T1DM. MCP-1 and activin-A levels were positively correlated. Clusterin levels showed a trend towards lower values in children with T1DM or obesity compared to the control group and were negatively correlated to renal function. Conclusions: The inflammation markers MCP-1, activin-A, and clusterin are not altered in children with T1DM. Conversely, obesity in children is positively correlated to serum MCP-1 values and characterized by higher activin-A levels, which may reflect an already established systematic inflammation with obesity since childhood.